Amphastar Pharma (AMPH) Tops Q3 EPS by 45c

Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $1.15, $0.45 better than the analyst estimate of $0.70. Revenue for the quarter came in at $180.6 million versus the consensus estimate of $174.63 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
• ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance